EASL 2012 Triple therapy Interferon-free regimens infohep news Triple therapy Sofosbuvir + interferon/ribavirin cures 90% of people with hard-to-treat hepatitis C genotypes Liz Highleyman / 04 May 2013 Adding the second-generation HCV polymerase inhibitor sofosbuvir (formerly GS-7977) to pegylated interferon plus ribavirin led to a sustained response rate of 89% for treatment-naive patients with HCV genotype 1 in the NEUTRINO study, ... Therapies BI 201335 & BI 207127 and ribavirin shows good efficacy, including hepatitis C patients with cirrhosis Liz Highleyman / 15 May 2012 An interferon-free regimen of the hepatitis C virus (HCV) protease inhibitor BI 201335, the non-nucleoside polymerase inhibitor BI 207127, and ribavirin produced sustained virological response in 68% of previously untreated genotype 1 hepatitis C ... Blood disorders (anaemia, thrombocytopenia and neutropenia) Ribavirin dose reduction is effective for managing anaemia in patients using boceprevir or telaprevir Liz Highleyman / 11 May 2012 Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anaemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th ... Therapies Promising findings for therapeutic hepatitis C vaccine TG4040 Liz Highleyman / 09 May 2012 An investigational hepatitis C virus (HCV) therapeutic vaccine significantly improved the likelihood of sustained response to interferon-based therapy, according to a proof-of-concept study reported at the 47th International Liver Congress (EASL 2012) last month ... Hepatocellular carcinoma (HCC) Brivanib did not improve overall liver cancer survival, but did show anti-tumour activity Liz Highleyman / 30 April 2012 The experimental cancer drug brivanib did not lengthen overall survival for patients with hepatocellular carcinoma, but it did increase time to progression, demonstrating that it had anti-tumour activity, researchers reported at the 47th ... Therapies GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks Liz Highleyman / 30 April 2012 Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the ... Acute infection Incidence of hepatitis C re-infection and clearance may be understimated Michael Carter / 26 April 2012 The incidence of hepatitis C re-infection among high-risk individuals who have spontaneously cleared the infection may be higher than previously assumed, a modelling study published in the May 1st edition of the ... Therapies Abbott interferon-free HCV combinations show early promise in untreated patients Caspar Thomson / 23 April 2012 Two interferon-free antiviral regimens being developed by Abbott showed high hepatitis C cure rates in small studies of treatment-naïve patients presented last week at the International Liver Congress in Barcelona. Abbott is pursuing the ... Treatment for previous non-responders & relapsers Boceprevir a useful option for patients who did not respond to earlier course of hepatitis C therapy Michael Carter / 23 April 2012 A regimen of boceprevir with pegylated interferon and ribavirin achieved cure rates of between 40 and 68% in patients who did not respond to a previous course of hepatitis C therapy, data ... Side effects Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment Keith Alcorn / 20 April 2012 A real-world study of new hepatitis C protease inhibitors in the group of patients who have been told they should not wait for newer, experimental antivirals has shown a much higher rate ... View more > Editors' picks from other sources View more > Other pages in this section Latest news All the news Conference news Email bulletin archive